Loading...
•
Dec 31, 2022
Ocugen Q4 2022 Earnings Report
Ocugen reported Q4 2022 financial results and provided a business update.
Key Takeaways
Ocugen reported a net loss of $0.10 per share for the fourth quarter of 2022, compared to a net loss of $0.07 per share for the same period in 2021. Research and development expenses increased to $17.2 million from $7.1 million year-over-year, while general and administrative expenses decreased slightly to $6.9 million from $7.5 million.
Completed retinitis pigmentosa patient enrollment in OCU400 Phase 1/2 clinical trial.
Continued progress for programs targeting eye diseases with the submission of an IND application for OCU200.
Expanded portfolio now includes inhaled vaccines for COVID-19, seasonal flu, and a combination COVID-19+seasonal flu vaccine.
Following FDA concurrence in the fourth quarter of 2022 on a confirmatory Phase 3 clinical trial design for NeoCart, developing internal capabilities to move NeoCart into the clinic next year.
Forward Guidance
Ocugen estimates that its current cash, cash equivalents, and investments will enable it to fund its operations into the first quarter of 2024.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...